Long
CFMS BUY/LONG NOW READY! 0.8836 to potentially 3.900 by End 2022
TICKER CODE : CFMS
Company Name: CONFORMIS INC
Industry : Health Technology . Medical Specialties
Position Proposed: BUY
Entry : NOW READY (0.8836-1.2428)
1st Partial Take Profit: 1.5501 (AUG 2021-OCT 2021)
2nd Partial Take Profit: 2.0080 (Early Jan 2022-March 2022)
Expected Take Profit: 3.9000 (July 2022- OCT 2022)
STOP LOSS: 0.4617
Technical Analysis:
1. Large Inverted Head & Shoulders (Formed and now forming retracement)
2. Smaller Inverted Head & Shoulders (Forming)
3. Double Bottom Formation Forming (First Head - 0.4700, Second Head-0.6525)
4. Fibonacci Retracement at 0.786, Expansion Fibonacci Retracement indicates a potential BUY Opportunity
5. Small Flag Pattern Forming Now (4th Jan - 3rd May)
6. Safest Take Profit will land equivalent to the Flagpole length and level 1 of Fibonacci Expansion Grey Zone.
7. The Market should potentially reach our Expected Take Profit will also be at EMA 60
Company Name: CONFORMIS INC
Industry : Health Technology . Medical Specialties
Position Proposed: BUY
Entry : NOW READY (0.8836-1.2428)
1st Partial Take Profit: 1.5501 (AUG 2021-OCT 2021)
2nd Partial Take Profit: 2.0080 (Early Jan 2022-March 2022)
Expected Take Profit: 3.9000 (July 2022- OCT 2022)
STOP LOSS: 0.4617
Technical Analysis:
1. Large Inverted Head & Shoulders (Formed and now forming retracement)
2. Smaller Inverted Head & Shoulders (Forming)
3. Double Bottom Formation Forming (First Head - 0.4700, Second Head-0.6525)
4. Fibonacci Retracement at 0.786, Expansion Fibonacci Retracement indicates a potential BUY Opportunity
5. Small Flag Pattern Forming Now (4th Jan - 3rd May)
6. Safest Take Profit will land equivalent to the Flagpole length and level 1 of Fibonacci Expansion Grey Zone.
7. The Market should potentially reach our Expected Take Profit will also be at EMA 60
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.